Clinical and biological characteristics at diagnosis in patients who presented with autoimmune cytopenia versus patients without autoimmune cytopenia
| . | With autoimmune cytopenia (n = 70) . | Without autoimmune cytopenia (n = 867) . | P . |
|---|---|---|---|
| Median age, y (range) | 65.5 (33-89) | 66 (24-97) | NS |
| Male (%) | 63 | 57 | NS |
| WBC count, ×109/L (range) | 28.3 (4.8-461) | 20.4 (2.5-454) | NS |
| Hb level, ×109/L (range) | 12.7 (4.6-18.10) | 13.8 (5-18.5) | < .05* |
| Platelet count, ×109/L (range) | 155 (10-347) | 188 (10-483) | < .05* |
| ALC, ×109/L (range) | 20.4 (2.8-410) | 14.2 (0.95-445) | .004 |
| BM infiltration, % (range)† | 60 (15-99) | 53 (3-100) | .075 |
| Binet stage, n (%) | |||
| A | 37 (53) | 671 (79) | |
| B | 9 (13) | 131 (15) | < .05* |
| C | 24 (34) | 54 (6) | |
| PS < 2, n (%) | 64 (92) | 824 (95) | NS |
| B2M > 2.5 mg/L, n/N (%) | 24/44 (55) | 185/502 (37) | .02 |
| LDT < 12 mo, n/N (%) | 17/46 (37) | 107/515 (21) | .01 |
| ZAP-70 > 20%, n/N (%) | 18/35 (51) | 142/432 (33) | .02 |
| CD38 > 30%, n/N (%) | 16/33 (48) | 129/393 (33) | .07 |
| Unmutated IGHV, n/N (%) | 11/22 (50) | 67/131 (51) | NS |
| Poor risk cytogenetics, n/N (%)‡ | 3/24 (13) | 44/254 (17) | NS |
| Follow-up, y (range) | 6.5 (0-25) | 5.5 (0-25) | NS |
| . | With autoimmune cytopenia (n = 70) . | Without autoimmune cytopenia (n = 867) . | P . |
|---|---|---|---|
| Median age, y (range) | 65.5 (33-89) | 66 (24-97) | NS |
| Male (%) | 63 | 57 | NS |
| WBC count, ×109/L (range) | 28.3 (4.8-461) | 20.4 (2.5-454) | NS |
| Hb level, ×109/L (range) | 12.7 (4.6-18.10) | 13.8 (5-18.5) | < .05* |
| Platelet count, ×109/L (range) | 155 (10-347) | 188 (10-483) | < .05* |
| ALC, ×109/L (range) | 20.4 (2.8-410) | 14.2 (0.95-445) | .004 |
| BM infiltration, % (range)† | 60 (15-99) | 53 (3-100) | .075 |
| Binet stage, n (%) | |||
| A | 37 (53) | 671 (79) | |
| B | 9 (13) | 131 (15) | < .05* |
| C | 24 (34) | 54 (6) | |
| PS < 2, n (%) | 64 (92) | 824 (95) | NS |
| B2M > 2.5 mg/L, n/N (%) | 24/44 (55) | 185/502 (37) | .02 |
| LDT < 12 mo, n/N (%) | 17/46 (37) | 107/515 (21) | .01 |
| ZAP-70 > 20%, n/N (%) | 18/35 (51) | 142/432 (33) | .02 |
| CD38 > 30%, n/N (%) | 16/33 (48) | 129/393 (33) | .07 |
| Unmutated IGHV, n/N (%) | 11/22 (50) | 67/131 (51) | NS |
| Poor risk cytogenetics, n/N (%)‡ | 3/24 (13) | 44/254 (17) | NS |
| Follow-up, y (range) | 6.5 (0-25) | 5.5 (0-25) | NS |
NS indicates not significant; WBC, white blood cell; Hb, hemoglobin; ALC, absolute lymphocyte count; BM, bone marrow; PS, performance status; B2M, β-2 microglobulin; LDT, lymphocyte doubling time; and ZAP-70, ζ-associated protein 70.
Significant differences are due to immune cytopenias.
Assessed by BM aspirate or biopsy or both.
Poor cytogenetics include del 17p, del 11q, trisomy 12, and the presence of ≥ 2 cytogenetic abnormalities as determined by fluorescence in situ hybridization and conventional cytogenetics.